PubMed Health⌕ Search

Biomedical subjects

M R Averna

Publications and source records attributed to M R Averna.

At least 55 records · Page 3Linked to original sources
PubMed1991

Lipids, lipoproteins and apolipoproteins AI, AII, B, CII, CIII and E in newborns.

In this study lipid and apolipoprotein patterns were investigated at birth and compared with those of adults. In cord sera, cholesterol, triglycerides, low-density lipoprotein (LDL) cholesterol and high-density lipoprotein (HDL) cholesterol were 38.2, 46.2, 50.5, and 31.9%, respectively, of adult values. Apolipoprotein AII, B and CIII were 48.6, 30.6 and 44.5% of adult values, while apo AI, apo CII and apo E showed values approaching those of adults (63.4, 73.3 and 89.7%, respectively). Also cholesterol/HDL cholesterol and LDL cholesterol/HDL cholesterol ratios were lower in newborns. In cord sera, lipids were correlated with various apolipoproteins in a surprisingly different way from adult sera. HDL cholesterol was not inversely correlated with triglycerides, and showed a highly positive correlation with apo E, apo CII and apo CIII, which did not correlate with HDL cholesterol in adults. These data supported the presence of significant differences in plasma concentrations and composition of lipoproteins at birth. Therefore HDL, apo CII, and apo E seem to play a different and more important metabolic role in neonatal lipid metabolism.

Apolipoproteins↗
PubMed1990

[Short-term metabolic compensation improves the lipo-apoprotein profile in type II diabetics in secondary insufficiency].

In the present study the effect of short-term metabolic control on plasma lipids and apoproteins in a group of subjects with type II diabetes mellitus in insulin treatment for secondary failure to oral agent therapy (sulphonylureas) was examined. For this reason 40 diabetic patients and 40 normal controls were studied. The lipoapoproteic pattern at the admission in the study and after a steady metabolic control, achieved by conventional insulin therapy and estimated by seric fructosamine, was evaluated. Diabetic patients, when compared with normal controls, showed a more atherogenic lipo-apoproteic profile and after achieving metabolic control, showed a reduction of triglyceride and apo B levels and a significant increase of the apo AI levels. The achievement of a good metabolic control, even after a short time, was associated with an improvement of the lipo-apoproteic profile, altered in diabetes mellitus in secondary failure.

Apoproteins↗
PubMed1989

Serum apolipoprotein profile of hypertriglyceridemic patients with chronic renal failure on hemodialysis: a comparison with type IV hyperlipoproteinemic patients.

Thirty-three patients with chronic renal failure (CRF) and uremic hypertriglyceridemia (HTG) on hemodialysis were compared with 33 type IV hyperlipoproteinemic patients matched for age, body mass index (BMI), and triglyceride (TG) levels. The two forms of hypertriglyceridemia showed different apolipoprotein profiles: apo AI, AII, and B levels and apo CII:CIII and TG:apo CIII ratios of CRF-HTG patients were lower and apo CIII levels were higher than the levels of type IV subjects.

Apolipoproteins↗
PubMed1989

[Effect of a long-term treatment with simvastatin, an inhibitor of HMG-CoA reductase, in dyslipidemic patients at high risk].

The reduction of total and LDL cholesterol (TC and LDLc), apoprotein B (ApoB) and in some instances triglycerides (TG) and the increase of HDL cholesterol (HDLc) and apoprotein A (ApoA) seem to be associated to a reduced coronary risk. Aim of our work was to evaluate the effects of a chronic treatment with the HMG-CoA reductase inhibitor simvastatin (MK-733), in a group of 8 dyslipidemic patients, 5 women and 3 men, aged between 48 and 69 years (mean age 59 +/- 8 years) at high risk being already affected by clinical compliances of atherosclerosis and not previously controlled by diet and/or other antidyslipidemic drugs. At the beginning and at the end (6 months) of this open study it was performed a clinical, ECG and ophthalmological examination, as well as an evaluation of the routine laboratory parameters. The initial dosage of simvastatin was a tablet of 10 mg/day, increased after a month to 20 mg and then to 40 mg/die. The mean dosage was 26.25 mg at the 3rd month and 21.25 mg at the 6th. Long-term simvastatin treatment was well tolerated (lack of important side effects as well as of significant changes of other clinical and laboratory parameters) and effective, reducing significantly (p less than 0.01) TC (317.9 +/- 30.8 vs 238.5 +/- 37.9 mg/dl), LDLc (210.6 +/- 48 vs 147.9 +/- 52 mg/dl), ApoB (144.7 +/- 17.5 vs 104.5 +/- 18), and TG (272.9 +/- 184 vs 200.5 +/- 117.6 mg/dl) and increasing in contrast HDL and ApoA values.(ABSTRACT TRUNCATED AT 250 WORDS)

Aged↗
PubMed1984

[Serum monoamine oxidase (MAO) as a prognostic indicator in chronic active hepatitis. II].

Aim of this study was to evaluate the prognostic value of sMAO activity, assayed by benzylamine colorimetric method. Has been studied the correlation between clinical signs of portal hypertension (splenomegaly, ascites and varices) and sMAO levels; there was a significant increase of enzyme activity in chronic active hepatitis (CAH) with splenomegaly vs. CAH without, and in liver cirrhosis (LC) with splenomegaly and/or varices vs. LC without; there was also a correlation between sMAO and gamma-globulins levels in CAH and not in LC patients. In conclusion has been discussed the prognostic value of sMAO activity in CAH.

Colorimetry↗
PubMed1984

[Serum monoamine oxidase (MAO) in the differential diagnosis of chronic liver disease. I].

Aim of this study was to evaluate the diagnostic value of serum MAO activity (sMAO) in chronic liver disease. sMAO has been assayed by benzylamine colorimetric method. No statistically significant differences of sMAO values have been found between controls and acute viral hepatitis or various diseases patients. Differences instead between controls and patients sMAO values (chronic persistent hepatitis, chronic active hepatitis and liver cirrhosis) were statistically significant (p less than 0.005).

Acute Disease↗
PubMed1983

[Glucose compensation, serum lipids and thyroid hormones (rT3 and rT3/T3 ratio in non-insulin-dependent (type 2) diabetics: 2].

In 45 type 2 diabetics it was unable to be found a relation between the plasma lipids and the fasting blood glucose (G), HbA1c, reverse T3 (rT3), rT3/T3 ratio, and relative body weight (R.B.W.). The conclusion was reached that the alteration of the lipoprotein metabolism and the thyroid hormones in type 2 diabetics could be primitive and independent from the availability of the insulin.

Adult↗
PubMed1983

Determination of HDL-cholesterol. Comparison between two methods.

We have evaluated a new method for HDL Cholesterol assay, using heparin-CaCl2-NaCl2. This method is in good correlation with PTA-MgCl2 technique. Our results are precise and accurate. HDL Cholesterol mean values: Normolipemic subjects, Cholesterol 190 +/- 13 mg% - Triglycerides 95 +/- 25 mg% - HDL-C 40.99 +/- 8.76 mg%; Ipertrigliceridemic subjects, Cholesterol 235 +/- 20 mg% - Triglcerides 284 +/- 30 mg% - HDL-C 30 +/- 4.7 mg%.

Cholesterol↗
PubMed1982

Apo-lipoproteic pattern in type II diabetics (I.I.D.) with macroangiopathy and with no apparent clinico-instrumental signs of microangiopathy.--Note I.

A significant increase of Tg, Tg-VLDL, C, C-VLDL, C-LDL and apo B, a reduction of C-HDL/C ratio and no difference in C-HDL were evidenced in 31 compensated macroangiopathic I.I.D.. No significant differences were noticed dividing the 31 I.I.D. in two groups according to their sex; C-HDL was higher in the females. Our results agree with those of Reckless and Schönfeld. In conclusion we think that an association between macroangiopathy and lipoproteic alteration in compensated I.I.D. can be stated according to our data.

Apolipoproteins↗
PubMed1982

Apo-lipoproteic pattern in type I complicated diabetes (I.D.D.) with microangiopathy and with no clinico-instrumental signs of macroangiopathy.--Note II.

No significant changes of C, C-HDL, C-VLDL, C-LDL, C-HDL/C, Tg, Tg-VLDL and apo B were evidenced in 12 compensated microangiopathic I.D.D. in comparison with 20 healthy controls. Instead the analysis of the data obtained comparing the same I.D.D. with 10 decompensated microangiopathic I.D.D., selected with the same criteria, has pointed out no significant changes between the two groups as regards C, C-HDL, C-VLDL, C-LDL, C-HDL/C and a statistically significant increase of Tg and Tg-VLDL in the 10 decompensated I.D.D.. Our results agree with those of Nikkila and we think we can conclude that it is not possible to evidence a characteristic lipidic or lipoproteic "marker" in compensated microangiopathic I.D.D.

Adult↗
PubMed1981

[Serum lipoprotein fractions in chronic liver diseases with and without alcoholism].

Total serum cholesterol (C) and triglyceride (TG) levels, C and TG-VLDL, C-LDL and C-HDL, total apoprotein B (apo B) and albumin (alb.) have been studied in three groups of patients with liver cirrhosis (CE), persistent hepatitis (EPS) and alcoholic chronic liver disease (EA) divided in two sub-groups of 4 EPS and 4 CE, and have been compared with controls values. In all cases the diagnosis was made on liver biopsy C, C-LDL and C-HDL levels were significantly lower in EPS, C and C-LDL in EA and CE; comparing the three groups each other, the only statistically significant difference was found for C-HDL values, more elevated in the 4 cases of EPS with alcoholism than in CE and EPS without alcoholism.

Adult↗
PubMedDate not supplied

Apolipoprotein profile in type II diabetic patients with and without coronary heart disease.

Diabetes mellitus is frequently associated with lipid metabolism abnormalities. In the present study the lipid and apolipoprotein profiles have been compared in type II diabetic subjects with (n = 30) and without (n = 30) coronary heart disease (CHD). All subjects were studied after good metabolic control had been achieved. Significant differences in plasma lipids and apolipoproteins were seen in diabetic patients with CHD in comparison with diabetics without CHD. Patients with CHD presented higher total cholesterol, triglyceride, LDL-cholesterol, apo B, apo CII and apo CIII levels and total cholesterol/HDL-cholesterol and LDL-cholesterol HDL-cholesterol ratios and lower HDL-cholesterol values and apo A1/apo B ratio than the patients without CHD. The same findings were found in females; while male subjects with CHD had significantly increased total cholesterol, LDL-cholesterol and apo B levels and total cholesterol/HDL-cholesterol and LDL-cholesterol/HDL-cholesterol ratios and significantly decreased apo A1/apo B ratio compared with males without CHD. These findings support the concept that the apolipoprotein profile plays a remarkable role as risk factor for CHD in type II diabetes mellitus.

Aged↗